Multicenter Selective Lymphadenectomy for Melanoma Trial II: A Phase III Multicenter Randomized Trial of Sentinel Lymphadenectomy and Complete Lymph Node Dissection Versus Sentinel Lymphadenectomy Alone in Cutaneous Melanoma Patients with Molecular or Histopathological Evidence of Metastases in the Sentinel Node

MSLT-II is a phase III multicenter, prospective, randomized clinical trial to determine if LM/SL and CLND for tumor-positive SN improves melanoma-specific survival compared to LM/SL alone followed by observation with serial nodal ultrasound in subjects with histopathologic or molecular evidence of metastases in the SN.

Study Number: 

PH 47505

Principal Investigator: 
ClinicalTrials.Gov ID: 

To inquire about participating in these studies, call 1-877-ASK-RPCI (1-877-275-7724) or e-mail